TER-1754

Phase 1Small molecule

TER-1754 is one of 6 small molecule programs targeting Hereditary Hemorrhagic Telangiectasia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hereditary Hemorrhagic TelangiectasiaRecruiting

Hereditary Hemorrhagic TelangiectasiaPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Hereditary Hemorrhagic Telangiectasia

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

7 2

Bactroban

PPadagis LLC

Approved

—3

Inderal

WWyeth-Lederle Vaccines

Votrient

2 5

Ofev

Boehringer Ingelheim

Phase 2

1 6

TER-1754

TTerremoto Biosciences Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Hereditary Hemorrhagic Telangiectasia

NCT07255846

Clinical

Trials by Indication[1]

Hereditary Hemorrhagic Telangiectasia1 trial

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

Recruiting·TTerremoto Biosciences Inc.·Phase 1·NCT07255846·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TER-1754. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TER-1754 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TER-1754. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Terremoto Biosciences Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTerremoto Biosciences Inc.

TER-1754

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Hereditary Hemorrhagic Telangiectasia1 trial

References

Drug Info

Quick Facts

Related News